UNI-EN 9:Dissimination of monthly sales information
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 9 | / | 2023 | |||||||
| Date of issue: | 2023-02-01 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Dissimination of monthly sales information | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sofia, Bulgaria, February 1, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that in order to more accurately present and prevent deviations in the published information concerning the Company's monthly sales data, the Board of Directors of "Sopharma" AD adopted a decision to extend the deadline for the publication of the relevant information until the 20th of the month following the reporting period. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_2023_Monthly_sales_20th_espi.pdf SFA_2023_Monthly_sales_20th_espi.pdf | Dissimination of monthly sales information | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2023-02-01 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 10.4 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
